JCR Pharmaceuticals Launches Phase III Trial of JR-142, Long-Acting Growth Hormone Therapy
JCR Pharmaceuticals Co., Ltd. (TSE 4552) today announced the dosing of the first patient in its Phase III clinical trial of JR-142 (INN: redalsomatropin alfa) in Japan. This marks a significant milestone for the company in the development of JR-142,…
ZIVO Bioscience Reports Early Efficacy of Proprietary Ingredients Against Avian Influenza
ZIVO Bioscience, Inc. (OTCQB: ZIVO), a leading biotech and agtech R&D company focused on developing therapeutic, medicinal, and nutritional products derived from proprietary algal cultures, has announced positive preliminary results from a recent study. Conducted in collaboration with the University…
Quantum-Si Unveils Advances in Protein Variant Detection with ProteoVue™ Software
Quantum-Si Incorporated (Nasdaq: QSI), known as The Protein Sequencing Company™, has announced the submission of a new preprint paper to BioRxiv, showcasing the power of its proprietary bioinformatics tool, ProteoVue, in detecting and quantifying Single Amino Acid Variants (SAAVs). The…
Bruker Unveils 1.2 GHz NMR Spectrometer at Swiss Facility
Bruker has announced the installation of a 1.2 GHz Ascend™ Nuclear Magnetic Resonance (NMR) spectrometer at the Swiss High-field NMR Facility, a collaborative research center jointly operated by the University of Basel, ETH Zürich, and the University of Zürich. This…
MIRAILAB BIOSCIENCE Launches NMN Supplements and Cosmetics in Singapore
MIRAILAB BIOSCIENCE Inc. (Headquarters: Chuo-ku, Tokyo; CEO: Megumi Tanaka) has partnered with Global Ocean Distribution Pte Ltd (Headquarters: Circular Road; Director: Getty Poon) to introduce its premium supplement brand MIRAI LAB, which features β-Nicotinamide Mononucleotide (β-NMN), to the Singapore market.…
MedLumics Completes FIM Study, to Present AblaView® PFA Results at AF Symposium 2025
Peter Hinchliffe, CEO of MedLumics, stated, “This marks a key milestone in validating a definitive Atrial Fibrillation (AF) ablation system, utilizing Pulsed Field Ablation (PFA) and Optical Coherence Reflectometry (OCR) to monitor and confirm ablation success in real-time under direct…
Weave Survey Shows How Patients Use Online Resources in Healthcare Decisions
A recent survey commissioned by Weave (NYSE: WEAV) sheds light on how patients across different generations are increasingly turning to the internet for health-related information and how this influences their interactions with healthcare providers. The study, conducted among 1,000 U.S.-based…
Sorriso Pharmaceuticals Reports Positive Phase 1b Results for SOR102 in Ulcerative Colitis
Sorriso Pharmaceuticals, a biopharmaceutical company focused on developing novel oral antibodies for immune-mediated diseases, today announced positive results from its Phase 1b clinical trial of SOR102. This oral, dual-acting biologic targets TNFα and IL-23 and was tested in patients with…
Uno Health Launches Free Tool for Vulnerable Americans Amid Rising Costs
Uno Health, a service aimed at increasing access to benefits and savings for lower-income Americans, has launched the Uno Savings Guide. This free tool helps individuals of all ages, including Medicare and Medicaid recipients, by determining eligibility for financial benefit…
FlexIt Launches FlexTogether™, Revolutionizing Fitness and Global Connectivity
FlexIt, a leader in virtual fitness and wellness, is excited to announce the launch of FlexTogether™, a groundbreaking platform designed to connect individuals globally through innovative wellness experiences. This new initiative features FlexIt’s proprietary AI Class Creator™ Technology, which enhances…
Jacques Gilbert Named Chief Strategy and Business Development Officer at Topcon Healthcare
Topcon Healthcare, Inc., a leading provider of medical devices and digital healthcare solutions, is excited to announce the appointment of Jacques Gilbert as Chief Strategy and Business Development Officer. In this key role, Jacques will spearhead the development and execution…
LimmaTech’s Staphylococcus aureus Vaccine Candidate Gets FDA Fast Track Status
LimmaTech Biologics AG, a clinical-stage biotech company focused on developing vaccines for life-threatening diseases, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its multivalent toxoid vaccine candidate, LBT-SA7. The vaccine is designed…